These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 27472395)

  • 1. IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin.
    O'Flanagan CH; O'Shea S; Lyons A; Fogarty FM; McCabe N; Kennedy RD; O'Connor R
    Oncotarget; 2016 Aug; 7(35):56826-56841. PubMed ID: 27472395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.
    Gomes LR; Rocha CRR; Martins DJ; Fiore APZP; Kinker GS; Bruni-Cardoso A; Menck CFM
    Cell Death Dis; 2019 Jun; 10(6):459. PubMed ID: 31189884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
    Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
    Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
    Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
    Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
    Biskup E; Naym DG; Gniadecki R
    J Dermatol Sci; 2016 Dec; 84(3):239-247. PubMed ID: 27743911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
    Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
    Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
    Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
    Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
    Mohni KN; Thompson PS; Luzwick JW; Glick GG; Pendleton CS; Lehmann BD; Pietenpol JA; Cortez D
    PLoS One; 2015; 10(5):e0125482. PubMed ID: 25965342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin.
    Hahm ER; Lee J; Abella T; Singh SV
    Mol Carcinog; 2019 Nov; 58(11):2139-2148. PubMed ID: 31441116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.
    Alsubhi N; Middleton F; Abdel-Fatah TM; Stephens P; Doherty R; Arora A; Moseley PM; Chan SY; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Martin SG; Curtin NJ; Madhusudan S
    Mol Oncol; 2016 Feb; 10(2):213-23. PubMed ID: 26459098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like Growth Factor 1 Receptor Signaling Is Required for Optimal ATR-CHK1 Kinase Signaling in Ultraviolet B (UVB)-irradiated Human Keratinocytes.
    Kemp MG; Spandau DF; Simman R; Travers JB
    J Biol Chem; 2017 Jan; 292(4):1231-1239. PubMed ID: 27979966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor-1 signaling is responsible for cathepsin G-induced aggregation of breast cancer MCF-7 cells.
    Morimoto-Kamata R; Yui S
    Cancer Sci; 2017 Aug; 108(8):1574-1583. PubMed ID: 28544544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.
    Teng PN; Bateman NW; Darcy KM; Hamilton CA; Maxwell GL; Bakkenist CJ; Conrads TP
    Gynecol Oncol; 2015 Mar; 136(3):554-61. PubMed ID: 25560806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis.
    Davaadelger B; Perez RE; Zhou Y; Duan L; Gitelis S; Maki CG
    Cancer Biol Ther; 2017 Nov; 18(11):895-903. PubMed ID: 28696156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
    Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
    Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
    Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
    Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
    Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
    Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549.
    Franks SE; Jones RA; Briah R; Murray P; Moorehead RA
    BMC Res Notes; 2016 Mar; 9():134. PubMed ID: 26928578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
    Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Vishwamitra D; Wang Y; Maywald RL; Buford AS; Fokt I; Skora S; Wang J; Naing A; Lazar AJ; Rohren EM; Daw NC; Subbiah V; Benjamin RS; Ratan R; Priebe W; Mikos AG; Amin HM; Ludwig JA
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27576731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FES-related tyrosine kinase activates the insulin-like growth factor-1 receptor at sites of cell adhesion.
    Stanicka J; Rieger L; O'Shea S; Cox O; Coleman M; O'Flanagan C; Addario B; McCabe N; Kennedy R; O'Connor R
    Oncogene; 2018 Jun; 37(23):3131-3150. PubMed ID: 29540831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.